CD19 and leukemia: As known from alternative CD19-targeted therapies including CD19 antibody therapy and BiTE therapy using blinatumomab, insufficient leukemia control leads to an increased risk of CD19− relapse and extramedullary leukemia formation, driven by the evolutionary pressure put on leukemia [16,82].